中國投資開發(00204.HK)訂立補充協議以修訂配售價 11月10日期復牌
格隆匯 11 月 9日丨中國投資開發(00204.HK)發佈公告,2020年11月9日,公司與配售代理就配售事項訂立補充協議以修訂配售價。根據補充協議,配售價由每股配售股份0.100港元修訂為每股配售股份0.101港元。配售價每股配售股份0.101港元較11月6日收市價每股0.125港元折讓約19.20%。
應公司要求,股份自2020年11月9日上午九時正起暫停於聯交所買賣,以待刊發本公告。公司已向聯交所作出申請,自2020年11月10日上午九時正起恢復股份於聯交所買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.